UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended |
Or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from | to |
Commission File No. | |
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification Number) |
(Address of principal executive offices) |
(Zip Code) |
( (Registrant’s telephone number) |
N/A |
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the close of the latest practical date.
Class | Outstanding at May 4, 2022 | |
Common Stock, $.001 Par Value | shares |
PERMA-FIX ENVIRONMENTAL SERVICES, INC.
INDEX
PART I - FINANCIAL INFORMATION
Item 1. – Financial Statements
PERMA-FIX ENVIRONMENTAL SERVICES, INC.
Consolidated Balance Sheets
March 31, | December 31, | |||||||
2022 | 2021 | |||||||
(Amounts in Thousands, Except for Share and Per Share Amounts) | (Unaudited) | (Audited) | ||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | $ | ||||||
Accounts receivable, net of allowance for doubtful accounts of $ | ||||||||
Unbilled receivables | ||||||||
Inventories | ||||||||
Prepaid and other assets | ||||||||
Current assets related to discontinued operations | ||||||||
Total current assets | ||||||||
Property and equipment: | ||||||||
Buildings and land | ||||||||
Equipment | ||||||||
Vehicles | ||||||||
Leasehold improvements | ||||||||
Office furniture and equipment | ||||||||
Construction-in-progress | ||||||||
Total property and equipment | ||||||||
Less accumulated depreciation | ( | ) | ( | ) | ||||
Net property and equipment | ||||||||
Property and equipment related to discontinued operations | ||||||||
Operating lease right-of-use assets | ||||||||
Intangibles and other long term assets: | ||||||||
Permits | ||||||||
Other intangible assets - net | ||||||||
Finite risk sinking fund (restricted cash) | ||||||||
Deferred tax assets | ||||||||
Other assets | ||||||||
Total assets | $ | $ |
The accompanying notes are an integral part of these consolidated financial statements.
1 |
PERMA-FIX ENVIRONMENTAL SERVICES, INC.
Consolidated Balance Sheets, Continued
March 31, | December 31 | |||||||
2022 | 2021 | |||||||
(Amounts in Thousands, Except for Share and per Share Amounts) | (Unaudited) | (Audited) | ||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | $ | ||||||
Accrued expenses | ||||||||
Disposal/transportation accrual | ||||||||
Deferred revenue | ||||||||
Accrued closure costs - current | ||||||||
Current portion of long-term debt | ||||||||
Current portion of operating lease liabilities | ||||||||
Current portion of finance lease liabilities | ||||||||
Current liabilities related to discontinued operations | ||||||||
Total current liabilities | ||||||||
Accrued closure costs | ||||||||
Long-term debt, less current portion | ||||||||
Long-term operating lease liabilities, less current portion | ||||||||
Long-term finance lease liabilities, less current portion | ||||||||
Long-term liabilities related to discontinued operations | ||||||||
Total long-term liabilities | ||||||||
Total liabilities | ||||||||
Commitments and Contingencies (Note 9 ) | ||||||||
Stockholders’ Equity: | ||||||||
Preferred Stock, $ | par value; shares authorized, shares issued and outstanding||||||||
Common Stock, $ | par value; shares authorized; and shares issued, respectively; and shares outstanding, respectively||||||||
Additional paid-in capital | ||||||||
Accumulated deficit | ( | ) | ( | ) | ||||
Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
Less Common Stock in treasury, at cost; | shares( | ) | ( | ) | ||||
Total stockholders’ equity | ||||||||
Total liabilities and stockholders’ equity | $ | $ |
The accompanying notes are an integral part of these consolidated financial statements.
2 |
PERMA-FIX ENVIRONMENTAL SERVICES, INC.
Consolidated Statements of Operations
(Unaudited)
Three Months Ended March 31, | ||||||||
(Amounts in Thousands, Except for Per Share Amounts) | 2022 | 2021 | ||||||
Revenues | $ | $ | ||||||
Cost of goods sold | ||||||||
Gross profit | ||||||||
Selling, general and administrative expenses | ||||||||
Research and development | ||||||||
Loss on disposal of property and equipment | ||||||||
Loss from operations | ( | ) | ( | ) | ||||
Other income (expense): | ||||||||
Interest income | ||||||||
Interest expense | ( | ) | ( | ) | ||||
Interest expense-financing fees | ( | ) | ( | ) | ||||
Other | ( | ) | ||||||
Loss from continuing operations before taxes | ( | ) | ( | ) | ||||
Income tax benefit | ( | ) | ( | ) | ||||
Loss from continuing operations, net of taxes | ( | ) | ( | ) | ||||
Loss from discontinued operations (net of taxes) (Note 10) | ( | ) | ( | ) | ||||
Net loss | ( | ) | ( | ) | ||||
Net loss attributable to non-controlling interest | ( | ) | ||||||
Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders | $ | ( | ) | $ | ( | ) | ||
Net loss per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - basic and diluted: | ||||||||
Continuing operations | $ | ( | ) | $ | ( | ) | ||
Discontinued operations | ( | ) | ( | ) | ||||
Net loss per common share | $ | ( | ) | $ | ( | ) | ||
Number of common shares used in computing net loss per share: | ||||||||
Basic | ||||||||
Diluted |
The accompanying notes are an integral part of these condensed consolidated financial statements.
3 |
PERMA-FIX ENVIRONMENTAL SERVICES, INC.
Consolidated Statements of Comprehensive Loss
(Unaudited)
Three Months Ended March 31, | ||||||||
(Amounts in Thousands) | 2022 | 2021 | ||||||
Net loss | $ | ( | ) | $ | ( | ) | ||
Other comprehensive income: | ||||||||
Foreign currency translation gain | ||||||||
Total other comprehensive income | ||||||||
Comprehensive loss | ( | ) | ( | ) | ||||
Comprehensive loss attributable to non-controlling interest | ( | ) | ||||||
Comprehensive loss attributable to Perma-Fix Environmental Services, Inc. stockholders | $ | ( | ) | $ | ( | ) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
4 |
PERMA-FIX ENVIRONMENTAL SERVICES, INC
Consolidated Statement of Stockholders’ Equity
(Unaudited)
(Amounts in thousands, except for share amounts)
Common Stock | Additional Paid-In | Common Stock Held In | Accumulated Other Comprehensive | Non-controlling Interest in | Accumulated | Total Stockholders’ | ||||||||||||||||||||||||||
Shares | Amount | Capital | Treasury | Loss | Subsidiary | Deficit | Equity | |||||||||||||||||||||||||
Balance at December 31, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | |||||||||||||||||||
Net loss | — | ( | ) | ( | ) | |||||||||||||||||||||||||||
Foreign currency translation | — | |||||||||||||||||||||||||||||||
Issuance of Common Stock for services | ||||||||||||||||||||||||||||||||
Stock-Based Compensation | — | |||||||||||||||||||||||||||||||
Balance at March 31, 2022 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | |||||||||||||||||||
Balance at December 31, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||
Net loss | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
Foreign currency translation | — | |||||||||||||||||||||||||||||||
Issuance of Common Stock for services | ||||||||||||||||||||||||||||||||
Stock-Based Compensation | — | |||||||||||||||||||||||||||||||
Balance at March 31, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ |
The accompanying notes are an integral part of these condensed consolidated financial statements.
5 |
PERMA-FIX ENVIRONMENTAL SERVICES, INC.
Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended | ||||||||
March 31, | ||||||||
(Amounts in Thousands) | 2022 | 2021 | ||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | ( | ) | $ | ( | ) | ||
Less: loss from discontinued operations, net of taxes (Note 10) | ( | ) | ( | ) | ||||
Loss from continuing operations, net of taxes | ( | ) | ( | ) | ||||
Adjustments to reconcile loss from continuing operations to cash provided by (used in) operating activities : | ||||||||
Depreciation and amortization | ||||||||
Interest on finance lease with purchase option | ||||||||
Amortization of debt issuance costs | ||||||||
Deferred tax benefit | ( | ) | ||||||
Recovery of bad debt reserves | ( | ) | ( | ) | ||||
Loss on disposal of plant, property, and equipment | ||||||||
Issuance of common stock for services | ||||||||
Stock-based compensation | ||||||||
Changes in operating assets and liabilities of continuing operations: | ||||||||
Accounts receivable | ( | ) | ||||||
Unbilled receivables | ||||||||
Prepaid expenses, inventories and other assets | ||||||||
Accounts payable, accrued expenses and unearned revenue | ( | ) | ( | ) | ||||
Cash provided by (used in) continuing operations | ( | ) | ||||||
Cash used in discontinued operations | ( | ) | ( | ) | ||||
Cash provided by (used in) operating activities | ( | ) | ||||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | ( | ) | ( | ) | ||||
Proceeds from sale of plant, property, and equipment | ||||||||
Cash used in investing activities of continuing operations | ( | ) | ( | ) | ||||
Cash flows from financing activities: | ||||||||
Repayments of revolving credit borrowings | ( | ) | ( | ) | ||||
Borrowing on revolving credit | ||||||||
Principal repayments of finance lease liabilities | ( | ) | ( | ) | ||||
Principal repayments of long term debt | ( | ) | ( | ) | ||||
Payment of debt issuance costs | ( | ) | ||||||
Cash used in financing activities | ( | ) | ( | ) | ||||
Effect of exchange rate changes on cash | ( | ) | ||||||
(Decrease) increase in cash and finite risk sinking fund (restricted cash) | ( | ) | ( | ) | ||||
Cash and finite risk sinking fund (restricted cash) at beginning of period | ||||||||
Cash and finite risk sinking fund (restricted cash) at end of period | $ | $ | ||||||
Supplemental disclosure: | ||||||||
Interest paid | $ | $ | ||||||
Income taxes paid | ||||||||
Non-cash investing and financing activities: | ||||||||
Equipment purchase subject to finance lease | ||||||||
Equipment purchase subject to financing |
The accompanying notes are an integral part of these condensed consolidated financial statements.
6 |
PERMA-FIX ENVIRONMENTAL SERVICES, INC.
Notes to Consolidated Financial Statements
March 31, 2022
(Unaudited)
Reference is made herein to the notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.
1. | Basis of Presentation |
The consolidated financial statements included herein have been prepared by the Company (which may be referred to as we, us or our), without an audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“the Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes the disclosures which are made are adequate to make the information presented not misleading. Further, the consolidated financial statements reflect, in the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2022.
The Company suggests that these consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
The
consolidated financial statements include the accounts of our wholly-owned subsidiaries and the account of a variable interest entity
(“VIE”), Perma-Fix ERRG for which we are the primary beneficiary (See “Note 13 - VIE” for a discussion of this
VIE). The consolidated financial statements for 2021 also included the accounts of the Company’s majority-owned Polish subsidiary,
Perma-Fix Medical S.A (“PFM Poland”) and PFM Poland’s wholly-owned subsidiary, Perma-Fix Medical Corporation (“PFMC”),
which comprised of the Company’s Medical Segment. As previously discussed, the Company made the strategic decision to cease all
research and development (“R&D”) activities under the Medical Segment and sold
Information for the Medical Segment is presented for the quarter ending March 31, 2021. The Medical Segment was disposed of as of December 31, 2021 and is not relevant for the quarter ending March 31, 2022. Prior period segment information is not required to be restated for the disposal of the segment.
2. | Summary of Significant Accounting Policies |
Our accounting policies are as set forth in the notes to the December 31, 2021 consolidated financial statements referred to above.
7 |
Recently Adopted Accounting Standards
In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, “Earnings Per Share (Topic 206), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force).” ASU 2021-04 addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This ASU is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The adoption of this ASU by the Company effective January 1, 2022 did not have a material impact on its financial statements.
Recently Issued Accounting Standards – Not Yet Adopted
In June 2016, the FASB issued ASU No. 2016-13, “Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments,” and various subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables and loans. Entities are required to apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. In November 2019, FASB issued ASU 2019-10, “Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date of ASU 2016-13 for public companies that are considered smaller reporting companies (“SRC”) as defined by the Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. These ASUs are effective January 1, 2023 for the Company as an SRC. Under new guidance issued by the Commission in March 2020, the Company continues to qualify as a smaller reporting company but became an accelerated filer starting with its 2021 Form 10-K and all subsequent filings. The Company is currently evaluating the impact of these ASU on its consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope,” which clarified the scope and application of the original guidance. The Company plans to adopt both ASUs when LIBOR is discontinued. The Company is currently evaluating the impact of the new ASUs on its condensed consolidated financial statements. As of the date of this report, the Company has determined that only its obligations under the credit facility as described in “Note 8 – Long Term Debt would be impacted by these ASUs. The Company’s obligations under its credit facility permit for payment of annual rate of interests on its obligations using prime rate or LIBOR.
In August 2020, the FASB issued ASU No. 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models and removing certain settlement condition qualifiers for the derivatives scope exception for contracts in an entity’s own equity, and simplifies the related diluted net income per share calculation for both Subtopics. ASU 2020-06 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, for the Company as an SRC. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and disclosures.
8 |
3. | Revenue |
Disaggregation of Revenue
In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of our services and provides meaningful disaggregation of each business segment’s results of operations. The nature of the Company’s performance obligations within our Treatment and Services Segments results in the recognition of our revenue primarily over time. The following tables present further disaggregation of our revenues by different categories for our Services and Treatment Segments:
Revenue by Contract Type | ||||||||||||||||||||||||
(In thousands) | Three Months Ended | Three Months Ended | ||||||||||||||||||||||
March 31, 2022 | March 31, 2021 | |||||||||||||||||||||||
Treatment | Services | Total | Treatment | Services | Total | |||||||||||||||||||
Fixed price | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
Time and materials | ||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | $ |
Revenue by generator | ||||||||||||||||||||||||
(In thousands) | Three Months Ended | Three Months Ended | ||||||||||||||||||||||
March 31, 2022 | March 31, 2021 | |||||||||||||||||||||||
Treatment | Services | Total | Treatment | Services | Total | |||||||||||||||||||
Domestic government | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
Domestic commercial | ||||||||||||||||||||||||
Foreign government | ||||||||||||||||||||||||
Foreign commercial | ||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | $ |
Contract Liabilities
The Company’s contract liabilities consist of deferred revenues which represent advance payment from customers in advance of the completion of our performance obligation. The following table represents changes in our contract liabilities balances:
Year-to-date | Year-to-date | |||||||||||||||
(In thousands) | March 31, 2022 | December 31, 2021 | Change ($) | Change (%) | ||||||||||||
Contract liabilities | ||||||||||||||||
Deferred revenue | $ | $ | $ | ( | ) | ( | )% |
The decrease was primarily due to revenue recognized in connection with a Services Segment contract. The decrease was also attributed to more processing of Treatment Segment’s backlog due to continued delays in waste receipts from certain customers from the impact of COVID-19.
During
the three months ended March 31, 2022 and 2021, the Company recognized revenue of $
Remaining Performance Obligations
The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.
Within our Services Segment, there are service contracts which provide that the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of our performance completed to date. For those contracts, the Company has utilized the practical expedient in ASC 606-10-55-18, which allows the Company to recognize revenue in the amount for which we have the right to invoice; accordingly, the Company does not disclose the value of remaining performance obligations for those contracts.
The Company’s contracts and subcontracts relating to activities at governmental sites generally allow for termination for convenience at any time at the government’s option without payment of a substantial penalty. The Company does not disclose remaining performance obligations on these contracts.
9 |
4. | Leases |
At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on facts and circumstances present in that arrangement. Lease classifications, recognition, and measurement are then determined at the lease commencement date.
The Company’s operating lease right-of-use (“ROU”) assets and operating lease liabilities represent primarily leases for office and warehouse spaces used to conduct our business. Finance leases consist primarily of processing and transport equipment used by our facilities’ operations.
The components of lease cost for the Company’s leases were as follows (in thousands):
Three Months Ended | ||||||||
March 31, | ||||||||
2022 | 2021 | |||||||
Operating Lease: | ||||||||
Lease cost | $ | $ | ||||||
Finance Leases: | ||||||||
Amortization of ROU assets | ||||||||
Interest on lease liability | ||||||||
Short-term lease rent expense | ||||||||
Total lease cost | $ | $ |
The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at March 31, 2022 were:
Operating Leases | Finance Leases | |||||||
Weighted average remaining lease terms (years) | ||||||||
Weighted average discount rate | % | % |
The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at March 31, 2021 were:
Operating Leases | Finance Leases | |||||||
Weighted average remaining lease terms (years) | ||||||||
Weighted average discount rate | % | % |
10 |
The following table reconciles the undiscounted cash flows for the operating and finance leases at March 31, 2022 to the operating and finance lease liabilities recorded on the balance sheet (in thousands):
Operating Leases | Finance Leases | |||||||
2022 (Remaining) | $ | $ | ||||||
2023 | ||||||||
2024 | ||||||||
2025 | ||||||||
2026 | ||||||||
2027 and thereafter | ||||||||
Total undiscounted lease payments | ||||||||
Less: Imputed interest | ( | ) | ( | ) | ||||
Present value of lease payments | $ | $ | ||||||
Current portion of operating lease obligations | $ | $ | — | |||||
Long-term operating lease obligations, less current portion | $ | $ | — | |||||
Current portion of finance lease obligations | $ | — | $ | |||||
Long-term finance lease obligations, less current portion | $ | — | $ |
Supplemental cash flow and other information related to our leases were as follows (in thousands):
Three Months Ended | ||||||||
March 31, | ||||||||
2022 | 2021 | |||||||
Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
Operating cash flow from operating leases | $ | $ | ||||||
Operating cash flow from finance leases | $ | $ | ||||||
Financing cash flow from finance leases | $ | $ | ||||||
ROU assets obtained in exchange for lease obligations for: | ||||||||
Finance liabilities | $ | $ | ||||||
Operating liabilities | $ | $ |
5. | Intangible Assets |
The following table summarizes information relating to the Company’s definite-lived intangible assets:
March 31, 2022 | December 31, 2021 | |||||||||||||||||||||||||||
Weighted Average Amortization | Gross | Net | Gross | Net | ||||||||||||||||||||||||
Period | Carrying | Accumulated | Carrying | Carrying | Accumulated | Carrying | ||||||||||||||||||||||
(Years) | Amount | Amortization | Amount | Amount | Amortization | Amount | ||||||||||||||||||||||
Other Intangibles (amount in thousands) | ||||||||||||||||||||||||||||
Patent | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | ||||||||||||||||||
Software | ( | ) | ( | ) | ||||||||||||||||||||||||
Customer relationships | ( | ) | ( | ) | ||||||||||||||||||||||||
Total | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ |
The intangible assets noted above are amortized on a straight-line basis over their useful lives with the exception of customer relationships which are being amortized using an accelerated method.
11 |
The following table summarizes the expected amortization over the next five years for our definite-lived intangible assets:
Amount | ||||
Year | (In thousands) | |||
2022 (Remaining) | $ | 164 | ||
2023 | 178 | |||
2024 | 46 | |||
2025 | 11 | |||
2026 | 11 |
Amortization
expenses relating to the definite-lived intangible assets as discussed above were $
6. | Capital Stock, Stock Plans, Warrants and Stock Based Compensation |
The Company has certain stock option plans under which it may award incentive stock options (“ISOs”) and/or non-qualified stock options (“NQSOs”) to employees, officers, outside directors, and outside consultants. No stock options were granted in the first quarter of 2022.
The Company granted a NQSO to Robert Ferguson on July 27, 2017 from the Company’s 2017 Stock Option Plan (“2017 Plan”) for the purchase of up to shares of the Company’s Common Stock (“Ferguson Stock Option”) in connection with his work as a consultant to the Company’s Test Bed Initiative (“TBI”) at our Perma-Fix Northwest Richland, Inc. (“PFNWR”) facility at an exercise price of $ per share, which was the fair market value of the Company’s Common Stock on the date of grant. The term of the Ferguson Stock Option is seven years from the grant date. The vesting of the Ferguson Stock Option is subject to the achievement of three separate milestones by certain dates. The first milestone was met and the shares under the first milestone were issued to Robert Ferguson in May 2018. The Company had previously entered into amendments whereby the vesting dates for the second and third milestones for the purchase of up to and shares of the Company’s Common Stock were extended to December 31, 2021 and December 31, 2022, respectively. On January 20, 2022, the Company’s Compensation and Stock Option Committee (“Compensation Committee”) and the Board of Directors (“Board”) further amended the vesting dates of the second and third milestones to December 31, 2022 and December 31, 2023, respectively. This amendment was approved by the Compensation Committee and the Board to take effect December 31, 2021. The Company has not recognized compensation costs (fair value of approximately $ at March 31, 2022) for the remaining Ferguson Stock Option under the remaining two milestones since achievement of the performance obligation under each of the two remaining milestones is uncertain at March 31, 2022. All other terms of the Ferguson Stock Option remain unchanged.
Three Months Ended | ||||||||
Stock Options | March 31, | |||||||
2022 | 2021 | |||||||
Employee Stock Options | $ | $ | ||||||
Director Stock Options | ||||||||
Total | $ | $ |
At
March 31, 2022, the Company has approximately $
12 |
The summary of the Company’s total Stock Option Plans as of March 31, 2022 and March 31, 2021, and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2010 Stock Option Plan, the 2017 Plan and the 2003 Outside Directors Stock Plan (“2003 Plan”):
Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (years) | Aggregate Intrinsic Value (3) | |||||||||||||
Options outstanding January 1, 2022 | $ | |||||||||||||||
Granted | $ | |||||||||||||||
Exercised | $ | $ | ||||||||||||||
Forfeited/expired | $ | |||||||||||||||
Options outstanding end of period (1) | $ | $ | ||||||||||||||
Options exercisable at March 31, 2022(1) | $ | $ |
Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (years) | Aggregate Intrinsic Value (3) | |||||||||||||
Options outstanding January 1, 2021 | $ | |||||||||||||||
Granted | ||||||||||||||||
Exercised | $ | |||||||||||||||
Forfeited/expired | ||||||||||||||||
Options outstanding end of period (2) | $ | $ | ||||||||||||||
Options exercisable at March 31, 2021(2) | $ | $ |
(1) |
(2) |
(3) |
During the three months ended March 31, 2022, the Company issued a total of shares of its Common Stock under the 2003 Plan to its outside directors as compensation for serving on our Board. The Company recorded approximately $ in compensation expenses (included in selling, general and administration (“SG&A”) expenses) in connection with the issuance of shares of its Common Stock to outside directors.
In
connection with a $
13 |
7. | Loss Per Share |
Three Months Ended | ||||||||
(Unaudited) | ||||||||
March 31, | ||||||||
(Amounts in Thousands, Except for Per Share Amounts) | 2022 | 2021 | ||||||
Net loss attributable to Perma-Fix Environmental Services, Inc., common stockholders: | ||||||||
Loss from continuing operations, net of taxes | $ | ( | ) | $ | ( | ) | ||
Net loss attributable to non-controlling interest | ( | ) | ||||||
Loss from continuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders | ( | ) | ( | ) | ||||
Loss from discontinuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders | ( | ) | ( | ) | ||||
Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders | $ | ( | ) | $ | ( | ) | ||
Basic loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders | $ | ( | ) | $ | ( | ) | ||
Diluted loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders | $ | ( | ) | $ | ( | ) | ||
Weighted average shares outstanding: | ||||||||
Basic weighted average shares outstanding | ||||||||
Add: dilutive effect of stock options | ||||||||
Add: dilutive effect of warrants | ||||||||
Diluted weighted average shares outstanding | ||||||||
Potential shares excluded from above weighted average share calculations due to their anti-dilutive effect include: | ||||||||
Stock options | ||||||||
Warrant |
8. | Long Term Debt |
Long-term debt consists of the following:
(Amounts in Thousands) | March 31, 2022 | December 31, 2021 | ||||||
Revolving Credit facility
dated May 8, 2020, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, balance due
on | $ | $ | ||||||
Term Loan dated May
8, 2020, payable in equal monthly installments of principal, balance due on | (2) | (2) | ||||||
Notes Payable to 2023 and 2025, annual interest
rate of | ||||||||
Total debt | ||||||||
Less current portion of long-term debt | ||||||||
Long-term debt | $ | $ |
(1) | ||
(2) |
14 |
Revolving Credit and Term Loan Agreement
The
Company entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated May 8, 2020 (“Loan
Agreement”), with PNC National Association (“PNC”), acting as agent and lender. The Loan Agreement provides the Company
with the following credit facility with a maturity date of
On March 29, 2022, the Company entered into an amendment to its Loan Agreement with its lender which provided, among other things, the following:
● | waived the Company’s failure to meet the minimum quarterly fixed charge coverage ratio (“FCCR”) requirement for the fourth quarter of 2021; | |
● | removes the quarterly FCCR testing requirement for the first quarter of 2022; | |
● | reinstates the quarterly FCCR testing requirement starting for the second quarter of 2022 and revises the methodology to be used in calculating the FCCR for the quarters ending June 30, 2022, September 30, 2022, and December 31, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter); | |
● | ||
● | revises
the annual rate used to calculate the Facility Fee (as defined in the Loan Agreement) on the revolving credit, with addition of the
capital expenditure line, from |
In
connection with the amendment, we paid PNC a fee of $
Pursuant
to the Loan Agreement, as amended, payment of annual rate of interest due on the revolving credit is at prime (
The Company may terminate its Loan Agreement, as amended, upon 90 days’ prior written notice upon payment in full of our obligations under the Loan Agreement. The Company has agreed to pay PNC 0.5% of the total financing if it pays off its obligations after May 7, 2021 but prior to or on May 7, 2022. No early termination fee will apply if the Company pays off its obligations under the Loan Agreement after May 7, 2022.
At
March 31, 2022, the borrowing availability under the Company’s revolving credit was approximately $
The Company’s credit facility under its Loan Agreement, as amended, with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. The Company was not required to perform testing of the FCCR requirement in the first quarter of 2022 pursuant to the March 29, 2022 amendment as discussed above, otherwise, it met all of its other financial covenant requirements.
15 |
9. | Commitments and Contingencies |
Hazardous Waste
In connection with our waste management services, the Company processes both hazardous and non-hazardous waste, which we transport to our own, or other, facilities for destruction or disposal. As a result of disposing of hazardous substances, in the event any cleanup is required at the disposal site, the Company could be a potentially responsible party for the costs of the cleanup notwithstanding any absence of fault on our part.
Legal Matters
In the normal course of conducting our business, we are involved in various litigation. We are not a party to any litigation or governmental proceeding which our management believes could result in any judgments or fines against us that could would have a material adverse effect on our financial position, liquidity or results of future operations.
Tetra Tech EC, Inc. (“Tetra Tech”)
During July 2020, Tetra Tech EC, Inc. (“Tetra Tech”) filed a complaint in the United States District Court for the Northern District of California (the “Court”) against CH2M Hill, Inc. (“CH2M”) and four subcontractors of CH2M, including the Company (“Defendants”). The complaint alleges various claims, including a claim for negligence, negligent misrepresentation, equitable indemnification and related business claims against all defendants related to alleged damages suffered by Tetra Tech in respect of certain draft reports prepared by defendants at the request of the U.S. Navy as part of an investigation and review of certain whistleblower complaints about Tetra Tech’s environmental restoration at the Hunter’s Point Naval Shipyard in San Francisco.
CH2M was hired by the Navy in 2016 to review Tetra Tech’s work. CH2M subcontracted with environmental consulting and cleanup firms Battelle Memorial Institute, Cabrera Services, Inc., SC&A, Inc. and the Company to assist with the review, according to the complaint.
Our insurance carrier is providing a defense on our behalf in connection with this lawsuit, subject to a $100,000 self-insured retention and the terms and limitations contained in the insurance policy.
On January 7, 2021, Defendants’ motion to dismiss the complaint in its entirety was granted without prejudice, with leave to amend. Tetra Tech subsequently filed a First Amended Complaint (“FAC”) and Defendants filed a motion to dismiss Tetra Tech’s FAC (the “Motion”). Tetra Tech filed an opposition to Defendant’s motion to dismiss Tetra Tech’s FAC. Defendants subsequently filed a joint reply to Tetra Tech’s motion in opposition. On January 27, 2022, the Motion was granted in part and denied in part by the Court. Tetra Tech’s claims for: (1) Negligence; (2) Equitable Indemnification/Contribution; and (3) Unfair Business Practices were dismissed. Tetra Tech was given leave to re-assert the Unfair Business Practices claim but chose not to do so, which means that claim is now also dismissed. Tetra Tech’s claims that survived the Motion are: (1) Intentional Interference with Contractual Relations; and (2) Inducing a Breach of Contract. The Company continues to believe it does not have any liability to Tetra Tech.
16 |
Perma-Fix Canada, Inc. (“PF Canada”)
During
the fourth quarter of 2021, PF Canada received a Notice of Termination (“NOT”) from Canadian Nuclear Laboratories, LTD. (“CNL”)
on a Task Order Agreement (“TOA”) that PF Canada entered into with CNL in May 2019 for remediation work within Ontario, Canada
(“Agreement”). The NOT was received after work under the TOA was substantially completed and work under the TOA has since
been completed. CNL may terminate the TOA at any time for convenience. As of March 31, 2022, PF Canada has approximately $
Insurance
The
Company has a
Letter of Credits and Bonding Requirements
From
time to time, the Company is required to post standby letters of credit and various bonds to support contractual obligations to customers
and other obligations, including facility closures. At March 31, 2022, the total amount of standby letters of credit outstanding was
approximately $
10. | Discontinued Operations |
The Company’s discontinued operations consist of all our subsidiaries included in our previous Industrial Segment which encompasses subsidiaries divested in 2011 and prior and three previously closed locations.
The
Company’s discontinued operations had net losses of $
17 |
The following table presents the major class of assets of discontinued operations as of March 31, 2022 and December 31, 2021. No assets and liabilities were held for sale at each of the periods noted.
March 31, | December 31, | |||||||
(Amounts in Thousands) | 2022 | 2021 | ||||||
Current assets | ||||||||
Other assets | $ | $ | ||||||
Total current assets | ||||||||
Long-term assets | ||||||||
Property, plant and equipment, net (1) | ||||||||
Total long-term assets | ||||||||
Total assets | $ | $ | ||||||
Current liabilities | ||||||||
Accounts payable | $ | $ | ||||||
Accrued expenses and other liabilities | ||||||||
Environmental liabilities | ||||||||
Total current liabilities | ||||||||
Long-term liabilities | ||||||||
Closure liabilities | ||||||||
Environmental liabilities | ||||||||
Total long-term liabilities | ||||||||
Total liabilities | $ | $ |
(1) |
11. | Operating Segments |
In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (1) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.
Our reporting segments are defined as below:
TREATMENT SEGMENT, which includes:
- | nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and | |
- | R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams. |
SERVICES SEGMENT, which includes:
- | Technical services, which include: |
○ | professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering; | |
○ | integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance; | |
○ | global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and | |
○ | on-site waste management services to commercial and governmental customers. |
18 |
- | Nuclear services, which include: |
○ | technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal; | |
○ | remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; logistics; transportation; and emergency response; and |
- | A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation. |
The
Company’s segment also included the Medical Segment in 2021. As previously discussed, the Company made the strategic decision
to cease all R&D activities under the Medical Segment and sold
Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 10 – Discontinued Operations”) which do not generate revenues.
The table below presents certain financial information of our operating segments for the three months ended March 31, 2022 and 2021 (in thousands):
Segment Reporting for the Quarter Ended March 31, 2022
Treatment | Services | Segments Total | Corporate(1) | Consolidated Total | ||||||||||||||||
Revenue from external customers | $ | $ | $ | $ | $ | |||||||||||||||
Intercompany revenues | ||||||||||||||||||||
Gross profit | ||||||||||||||||||||
Research and development | ||||||||||||||||||||
Interest income | ||||||||||||||||||||
Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
Interest expense-financing fees | ( | ) | ( | ) | ||||||||||||||||
Depreciation and amortization | ||||||||||||||||||||
Segment (loss) income before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Income tax benefit | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Segment income (loss) | ( | ) | ( | ) | ||||||||||||||||
Expenditures for segment assets | (2) |
Segment Reporting for the Quarter Ended March 31, 2021
Treatment | Services | Medical | Segments Total | Corporate(1) | Consolidated Total | |||||||||||||||||||
Revenue from external customers | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
Intercompany revenues | ||||||||||||||||||||||||
Gross profit | ||||||||||||||||||||||||
Research and development | ||||||||||||||||||||||||
Interest income | ||||||||||||||||||||||||
Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||
Interest expense-financing fees | ( | ) | ( | ) | ||||||||||||||||||||
Depreciation and amortization | ||||||||||||||||||||||||
Segment (loss) income before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Income tax benefit | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Segment (loss) income | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Expenditures for segment assets | (2) |
(1) | ||
(2) |
19 |
12. | Income Taxes |
The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes.
The
Company had income tax benefit of approximately $
13. | Variable Interest Entities (“VIE”) |
The
Company and Engineering/Remediation Resources Group, Inc. (“ERRG”) previously entered into an unpopulated joint venture agreement
for project work bids within the Company’s Services Segment with the joint venture doing business as Perma-Fix ERRG, a general
partnership. The Company has a
The Company determines whether joint ventures in which it has invested meet the criteria of a VIE at the start of each new venture and when a reconsideration event has occurred. A VIE is a legal entity that satisfies any of the following characteristics: (a) the legal entity does not have sufficient equity investment at risk; (b) the equity investors at risk as a group, lack the characteristics of a controlling financial interest; or (c) the legal entity is structured with disproportionate voting rights.
The Company consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.
Based
on the Company’s evaluation of Perma-Fix ERRG and related agreements with Perma-Fix ERRG, the Company determined that Perma-Fix
ERRG continues to be a VIE in which we are the primary beneficiary. At March 31, 2022, Perma-Fix ERRG had total assets of $
14. | Executive Compensation |
The
Company’s Compensation Committee and the Board determined that no performance payment would be made to each executive officer under
his 2021 Management Incentive Plan (“MIP”). In lieu of any performance payment to each executive officer under his 2021 MIP
and in an attempt to retain the executive officer, on January 20, 2022, the Compensation Committee and the Board determined that the
base annual compensation for each executive officer for 2022 is increased by approximately
On
January 20, 2022, the Board and the Compensation Committee also approved individual MIP for the calendar year 2022 for each of our executive
officers. Each MIP is effective January 1, 2022 and applicable for year 2022. Each MIP provides guidelines for the calculation of annual
cash incentive-based compensation, subject to Compensation Committee oversight and modification. The performance compensation under each
of the MIPs is based upon meeting certain of the Company’s separate target objectives during 2022. Assuming each target objective
is achieved under the same performance threshold range under each MIP, the total potential target performance compensation payable ranges
from
15. | Subsequent Events |
Management evaluated events occurring subsequent to March 31, 2022 through May 5, 2022, the date these consolidated financial statements were available for issuance, and determined that no material recognizable subsequent events occurred.
20 |
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
Forward-looking Statements
Certain statements contained within this report may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, the “Private Securities Litigation Reform Act of 1995”). All statements in this report other than a statement of historical fact are forward-looking statements that are subject to known and unknown risks, uncertainties and other factors, which could cause actual results and performance of the Company to differ materially from such statements. The words “believe,” “expect,” “anticipate,” “intend,” “will,” and similar expressions identify forward-looking statements. Forward-looking statements contained herein relate to, among other things,
● | demand for our services; |
● | reductions in the level of government funding in future years; |
● | reducing operating costs and non-essential expenditures; |
● | ability to meet loan agreement quarterly covenant requirements; |
● | cash flow requirements; |
● | Canadian receivable; |
● | sufficient liquidity to continue business; |
● | future results of operations and liquidity; |
● | effect of economic disruptions on our business; |
● | government funding for our services; |
● | may not have liquidity to repay debt if our lender accelerates payment of our borrowings; |
● | deployment of unit; |
● | manner in which the applicable government will be required to spend funding to remediate various sites; |
● | funding operations; |
● | continued increases in pricing and/or further tightening supply chain; |
● | fund capital expenditures from cash from operations and/or financing; |
● | impact from COVID-19 and impact from other delays; |
● | improvement in waste shipments; |
● | fund remediation expenditures for sites from funds generated internally; |
● | collection of accounts receivables; |
● | compliance with environmental regulations; |
● | potential effect of being a PRP; |
● | potential sites for violations of environmental laws and remediation of our facilities; |
21 |
● | remediation of material weakness; |
● | future price increases; and |
● | continuation of contracts with federal government. |
While the Company believes the expectations reflected in such forward-looking statements are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors, which could cause future outcomes to differ materially from those described in this report, including, but not limited to:
● | general economic conditions; |
● | contract bids, including international markets; |
● | material reduction in revenues; |
● | inability to meet PNC covenant requirements; |
● | inability to collect in a timely manner a material amount of receivables; |
● | increased competitive pressures; |
● | inability to maintain and obtain required permits and approvals to conduct operations; |
● | public not accepting our new technology; |
● | inability to develop new and existing technologies in the conduct of operations; |
● | inability to maintain and obtain closure and operating insurance requirements; |
● | inability to retain or renew certain required permits; |
● | discovery of additional contamination or expanded contamination at any of the sites or facilities leased or owned by us or our subsidiaries which would result in a material increase in remediation expenditures; |
● | delays at our third-party disposal site can extend collection of our receivables greater than twelve months; |
● | refusal of third-party disposal sites to accept our waste; |
● | changes in federal, state and local laws and regulations, especially environmental laws and regulations, or in interpretation of such; |
● | requirements to obtain permits for TSD activities or licensing requirements to handle low level radioactive materials are limited or lessened; |
● | potential increases in equipment, maintenance, operating or labor costs; |
● | management retention and development; |
● | financial valuation of intangible assets is substantially more/less than expected; |
● | the requirement to use internally generated funds for purposes not presently anticipated; |
● | inability to continue to be profitable on an annualized basis; |
● | inability of the Company to maintain the listing of its Common Stock on the NASDAQ; |
● | terminations of contracts with government agencies or subcontracts involving government agencies or reduction in amount of waste delivered to the Company under the contracts or subcontracts; |
● | renegotiation of contracts involving government agencies; |
● | federal government’s inability or failure to provide necessary funding to remediate contaminated federal sites; |
● | disposal expense accrual could prove to be inadequate in the event the waste requires re-treatment; |
● | inability to raise capital on commercially reasonable terms; |
● | inability to increase profitable revenue; |
● | impact of the COVID-19; |
● | delays in waste shipments and delay in activities under new contracts; |
● | new governmental regulations; |
● | lender refuses to waive non-compliance or revise our covenant so that we are in compliance; |
● | continued supply chain interruptions; |
● | continued inflationary pressures; |
● | other unanticipated factors; and |
● | risk factors and other factors set forth in “Special Note Regarding Forward-Looking Statements” contained in the Company’s 2021 Form 10-K and the “Forward-Looking Statements” contained in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”) of this first quarter 2022 Form 10-Q. |
22 |
COVID-19 Impact and Impact due to Other Delays
Our first quarter financial results continued to be impacted by COVID-19. As previously disclosed, within our Services Segment, we experienced delays in procurement actions and contract awards during the first half of 2021 resulting from the impact of COVID-19. Since the end of the second quarter of 2021, we were awarded a number of new contracts. However, due to continued COVID-19 impact and/or customer administrative delay experienced by certain customers, work under certain of our new awards was temporarily curtailed/delayed which continued for most of the first quarter of 2022 and negatively impacted revenue. We have, however, begun to see improvement in activities from certain of these new projects starting in the latter part of the first quarter of 2022. Our Treatment Segment revenue continues to be negatively impacted by continued waste shipment delays from certain customers since the latter part of the first quarter of 2020, the start of the pandemic. We expect to see a gradual improvement in waste receipts from these customers in the upcoming months as our customers start easing up on COVID-19 restrictions; however, such may not be the case based on our customers’ own responses to COVID-19, including, but not limited to delaying or limiting full return-to-work schedules. Additionally, as a result of supply chain challenges, we experienced a delay in the delivery of a new technology waste processing unit from our supplier which negatively impacted our revenue as associated revenue was not able to be generated. Delivery of this unit had been expected during the third quarter of 2021 but did not occur until the latter part of the first quarter of 2022. Deployment of this unit is expected to commence in the second quarter of 2022. Within our Treatment Segment, we are experiencing a large increase in proposal requests. We continue to have bids currently submitted in both segments and awaiting awards.
At this time, we believe we have sufficient liquidity on hand to continue business operations during the next twelve months. At March 31, 2022, we had borrowing availability under our revolving credit facility of approximately $4,544,000 which was based on a percentage of eligible receivables and subject to certain reserves. As a result of a recent amendment to our Loan Agreement, we are required to maintain a minimum of $3,000,000 in borrowing availability under our revolving credit until the minimum FCCR requirement for the quarter ended June 30, 2022 has been met and certified to our lender (see “Financing Activities” within this MD&A for a discussion of this amendment). We continue to assess the need in reducing operating costs during this volatile time, which may include curtailing certain capital expenditures and eliminating non-essential expenditures.
We are closely monitoring our customers’ payment performance. However, since a significant portion of our revenues is derived from government related contracts, we do not expect our accounts receivable collections to be materially impacted due to COVID-19.
As the situations surrounding COVID-19 continues to remain fluid, the full impact and extent of the pandemic on our financial results and liquidity cannot be estimated with any degree of certainty. We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including supply chain challenges, our labor force and increasing costs from inflationary pressures (see “Known Trends and Uncertainties” – “Supply Chain” and “Inflation and Cost Increases” within this MD&A).
23 |
Overview
Revenue decreased by $7,218,000 or 31.2% to $15,915,000 for the three months ended March 31, 2022 from $23,133,000 for the corresponding period of 2021. The decrease was primarily within our Services Segment where revenue decreased to $8,436,000 from $15,638,000 or approximately 46.1%. As discussed above, work under certain of the new projects awarded to our Services Segment at the end of the second quarter of 2021 continued to be delayed/curtailed for most of the first quarter of 2022 due to COVID-19 impact and/or administrative delays experienced by certain customers. However, we have begun to see improvement in activities from certain of these new projects starting in the latter part of the first quarter of 2022. The lower revenue in the first quarter of 2022 resulting from delays/curtailments in work was further exacerbated by the completion of a large project in the second quarter of 2021 which was not replaced with a similar size contract because of delays in contract awards and procurement from COVID-19 impact in the first half of 2021. Our Treatment Segment revenue decreased slightly by $16,000 or 0.2%. Although we saw minimal overall change in revenue within Treatment Segment, our Treatment Segment revenue has not returned to pre-pandemic levels as certain customers continue to delay waste shipments due to impact of COVID-19. Gross profit decreased $720,000 or 30.6%. Selling, General, and Administrative (“SG&A”) expenses increased $217,000 or 6.8% for the three months ended March 31, 2022 as compared to the corresponding period of 2021.
Business Environment
Our Treatment and Services Segments’ business continues to be heavily dependent on services that we provide to governmental clients, primarily as subcontractors for others who are prime contractors to government entities or directly as the prime contractor. We believe demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including, without limitation, the economic conditions, the manner in which the applicable government will be required to spend funding to remediate various sites, and/or potential further impact from COVID-19. In addition, our governmental contracts and subcontracts relating to activities at governmental sites in the United States are generally subject to termination for convenience at any time at the government’s option, and our governmental contracts/task orders with the Canadian government authorities also allow the authorities to terminate the contract/task orders at any time for convenience. Our work under all of our contracts/task order agreements with Canadian government authorities has substantially been completed. See “Known Trends and Uncertainties – Perma-Fix Canada, Inc. (“PF Canada”)” for additional discussion as to a terminated Canadian TOA. Significant reductions in the level of governmental funding or specifically mandated levels for different programs that are important to our business could have a material adverse impact on our business, financial position, results of operations and cash flows.
We are continually reviewing methods to raise additional capital to supplement our liquidity requirements, when needed, and reducing our operating costs. We continue to aggressively bid on various contracts, including potential contracts within the international markets.
Results of Operations
The reporting of financial results and pertinent discussions are tailored to our two reportable segments: The Treatment and Services. Our financial results for 2021 also included our Medical Segments. As previously disclosed, we made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of our interest in PFM Poland (which comprised the Medical Segment) in December 2021. Our Medical Segment had not generated any revenue and was involved in our medical isotope production technology. All costs previously incurred by the Medical Segment were included within R&D.
24 |
Summary – Three Months Ended March 31, 2022 and 2021
Three Months Ended | ||||||||||||||||
March 31, | ||||||||||||||||
Consolidated (amounts in thousands) | 2022 | % | 2021 | % | ||||||||||||
Revenues | $ | 15,915 | 100.0 | $ | 23,133 | 100.0 | ||||||||||
Cost of good sold | 14,279 | 89.7 | 20,777 | 89.8 | ||||||||||||
Gross profit | 1,636 | 10.3 | 2,356 | 10.2 | ||||||||||||
Selling, general and administrative | 3,422 | 21.5 | 3,205 | 13.9 | ||||||||||||
Research and development | 96 | .6 | 150 | .6 | ||||||||||||
Loss on disposal of property and equipment | 1 | — | — | — | ||||||||||||
Loss from operations | $ | (1,883 | ) | (11.8 | ) | $ | (999 | ) | (4.3 | ) | ||||||
Interest income | 11 | — | 18 | — | ||||||||||||
Interest expense | (35 | ) | (.2 | ) | (67 | ) | (.2 | ) | ||||||||
Interest expense-financing fees | (13 | ) | (.1 | ) | (8 | ) | — | |||||||||
Other | (2 | ) | — | 1 | — | |||||||||||
Loss from continuing operations before taxes | (1,922 | ) | (12.1 | ) | (1,055 | ) | (4.5 | ) | ||||||||
Income tax benefit | (673 | ) | (4.3 | ) | (17 | ) | — | |||||||||
Loss from continuing operations | $ | (1,249 | ) | (7.8 | ) | $ | (1,038 | ) | (4.5 | ) |
Revenues
Consolidated revenues decreased $7,218,000 for the three months ended March 31, 2022, compared to the three months ended March 31, 2021, as follows:
(In thousands) | 2022 | % Revenue | 2021 | % Revenue | Change | % Change | ||||||||||||||||||
Treatment | ||||||||||||||||||||||||
Government waste | $ | 5,437 | 34.2 | $ | 4,387 | 18.9 | $ | 1,050 | 23.9 | |||||||||||||||
Hazardous/non-hazardous (1) | 1,001 | 6.3 | 1,311 | 5.7 | (310 | ) | (23.6 | ) | ||||||||||||||||
Other nuclear waste | 1,041 | 6.5 | 1,797 | 7.8 | (756 | ) | (42.1 | ) | ||||||||||||||||
Total | 7,479 | 47.0 | 7,495 | 32.4 | (16 | ) | (0.2 | ) | ||||||||||||||||
Services | ||||||||||||||||||||||||
Nuclear services | 8,281 | 52.0 | 15,080 | 65.2 | (6,799 | ) | (45.1 | ) | ||||||||||||||||
Technical services | 155 | 1.0 | 558 | 2.4 | (403 | ) | (72.2 | ) | ||||||||||||||||
Total | 8,436 | 53.0 | 15,638 | 67.6 | (7,202 | ) | (46.1 | ) | ||||||||||||||||
Total | $ | 15,915 | 100.0 | $ | 23,133 | 100.0 | $ | (7,218 | ) | (31.2 | ) |
(1) Includes wastes generated by government clients of $470,000 and $745,000 for the three months ended March 31, 2022 and the corresponding period of 2021, respectively.
Treatment Segment revenue decreased slightly by $16,000 or 0.2% for the three months ended March 31, 2022 over the same period in 2021. The decrease in hazardous/non-hazardous revenue was primarily due to lower waste volume. Revenue from other nuclear waste was lower primarily due to lower averaged price waste. Waste from government generators increased by approximately $1,050,000 or 23.9% primarily due higher waste volume. Although we saw minimal overall change in revenue within Treatment Segment, our Treatment Segment revenue has not returned to pre-pandemic levels as certain customers continue to delay waste shipments due, in part, to impact of COVID-19. Our Services Segment revenue decreased by approximately $7,202,000 or 46.1%. Work under certain of the new projects awarded to our Services Segment at the end of the second quarter of 2021 continued to be delayed/curtailed for most of the first quarter of 2022 due to COVID-19 impact and/or administrative delays experienced by certain customers. However, we have begun to see improvement in activities from certain of these new projects starting in the latter part of the first quarter of 2022. The lower revenue in the first quarter of 2022 resulting from delays/curtailments in work was further exacerbated by the completion of a large project in the second quarter of 2021 which was not replaced with a similar size contract from delays in contract awards and procurement from COVID-19 impact in the first half of 2021. Our Services Segment revenues are project based; as such, the scope, duration and completion of each project vary. As a result, our Services Segment revenues are subject to differences relating to timing and project value.
25 |
Cost of Goods Sold
Cost of goods sold decreased $6,498,000 for the quarter ended March 31, 2022, compared to the quarter ended March 31, 2021, as follows:
% | % | |||||||||||||||||||
(In thousands) | 2022 | Revenue | 2021 | Revenue | Change | |||||||||||||||
Treatment | $ | 6,841 | 91.5 | $ | 6,570 | 87.7 | $ | 271 | ||||||||||||
Services | 7,438 | 88.2 | 14,207 | 90.8 | (6,769 | ) | ||||||||||||||
Total | $ | 14,279 | 89.7 | $ | 20,777 | 89.8 | $ | (6,498 | ) |
Cost of goods sold for the Treatment Segment increased by approximately $271,000 or 4.1%. The increased costs was primarily due to higher overall fixed costs of approximately $277,000 resulting from the following: general expenses were higher by $144,000 primarily due to higher utility costs; salaries and payroll related expenses were higher by approximately $49,000; depreciation expenses were higher by approximately $59,000 due to depreciation for asset retirement obligations in connection with our EWOC facility; regulatory expenses were higher by approximately $15,000; and travel expenses were higher by $10,000 resulting from easing up of COVID-19 restrictions. Treatment Segment’s variable costs decreased slightly by approximately $6,000 primarily due to lower overall costs in disposal, transportation, material and supplies which were mostly offset by higher outside services costs. Services Segment cost of goods sold decreased approximately $6,769,000 or 47.6% primarily due to lower revenue. The decrease in cost of goods sold was primarily due to lower salaries/payroll related, travel, and outside services expenses totaling $6,909,000. The overall lower costs were partially offset by higher material and supplies costs. Included within cost of goods sold is depreciation and amortization expense of $439,000 and $394,000 for the three months ended March 31, 2022, and 2021, respectively.
Gross Profit
Gross profit for the quarter ended March 31, 2022 decreased $720,000 over the corresponding period of 2021, as follows:
% | % | |||||||||||||||||||
(In thousands) | 2022 | Revenue | 2021 | Revenue | Change | |||||||||||||||
Treatment | $ | 638 | 8.5 | $ | 925 | 12.3 | $ | (287 | ) | |||||||||||
Services | 998 | 11.8 | 1,431 | 9.2 | (433 | ) | ||||||||||||||
Total | $ | 1,636 | 10.3 | $ | 2,356 | 10.2 | $ | (720 | ) |
Treatment Segment gross profit decreased by $287,000 or 31.0% and gross margin decreased to 8.5% from 12.3% primarily due to the impact of our fixed costs. Services Segment gross profit decreased by $433,000 or 30.3% and gross margin increased from 9.2% to 11.8%. Our overall Services Segment gross margin is impacted by our current projects which are competitively bid on and will therefore, have varying margin structures.
SG&A
SG&A expenses increased $217,000 for the three months ended March 31, 2022, as compared to the corresponding period for 2021, as follows:
(In thousands) | 2022 | % Revenue | 2021 | % Revenue | Change | |||||||||||||||
Administrative | $ | 1,687 | — | $ | 1,372 | — | $ | 315 | ||||||||||||
Treatment | 1,040 | 13.9 | 978 | 13.0 | 62 | |||||||||||||||